


Pharmaceutical Management Agency
New Zealand
Pharmaceutical Schedule

Section H Update

for Hospital Pharmaceuticals

September 2025

The background of the cover features a large, light gray circle containing the PHARMAC logo. Below the circle, there are stylized, concentric, wavy lines in white and light gray, resembling a stylized 'S' or a series of overlapping waves. The overall design is clean and modern, with a focus on the PHARMAC logo and the title.

PHARMAC
TE PĀTAKA WHAIORANGA

Contents

Summary of decisions effective 1 September 2025 3

Section H changes to Part II 7

Index 16

Summary of decisions

EFFECTIVE 1 SEPTEMBER 2025

- Abacavir sulphate with lamivudine (Abacavir/lamivudine Viatris) tab 600 mg with lamivudine 300 mg – price increase and addition of PSS
- Aciclovir (Lovir) tab dispersible 200 mg, 400 mg and 800 mg – price increase and addition of PSS
- Adalimumab (Amgevita) inj 20 mg per 0.4 ml prefilled syringe, inj 40 mg per 0.8 ml prefilled pen and inj 40 mg per 0.8 ml prefilled syringe – amended restriction criteria
- Amiodarone hydrochloride tab 100 mg and 200 mg (Aratac) and inj 50 mg per ml, 3 ml ampoule (Max Health) – price increase and addition of PSS
- Amino acid formula (without phenylalanine and tyrosine) (TYR Lophlex LQ 20) liquid (juicy berries), 20 g protein, 12.75 g carbohydrate and 0.46 g fat and 0 g fibre per 125 ml pouch – new listing
- Amino acid formula (without phenylalanine and tyrosine) (TYR Lophlex LQ 20) liquid (juicy berries), 20 g protein, 8.8 g carbohydrate 0.44 g fat and 0.5 g fibre per 125 ml pouch – to be delisted 1 December 2025
- Amoxicillin (Miro-Amoxicillin) cap 250 mg – price increase and addition of PSS
- Aspirin (Ethics Aspirin EC) tab 100 mg, 90 tab pack – delisted 1 September 2025
- Atazanavir sulphate (Atazanavir Viatris) cap 150 mg and 200 mg – price increase and addition of PSS
- Azathioprine (Azamun) tab 25 mg and 50 mg – price increase and addition of PSS
- Benzathine benzylpenicillin (Benzetacil) inj 900 mg (1.2 million units) vial – new listing
- Benztropine mesylate (Bentrop) tab 2 mg – price increase
- Bupivacaine hydrochloride with fentanyl (Bupafen) inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag and 200 ml bag – price increase and addition of PSS
- Capecitabine (Capecitabine Viatris) tab 150 mg and 500 mg – price increase and addition of PSS
- Carbamazepine (Tegretol AU) tab 200 mg – delisted 1 September 2025
- Cefaclor (Ranbaxy-Cefaclor) cap 250 mg and grans for oral liq 25 mg per ml, 100 ml – price increase and addition of PSS
- Ceftriaxone (Ceftriaxone-AFT) inj 500 mg vial and 2 g vial – price increase and addition of PSS
- Ceftriaxone (Ceftriaxone-AFT) inj 1 g vial – price decrease and addition of PSS
- Celecoxib (Celebrex) cap 100 mg – new listing and addition of PSS
- Celecoxib (Celecoxib Pfizer) cap 100 mg – to be delisted 1 February 2026
- Charcoal (Carbosorb-X) oral liq 200 mg per ml, 250 ml – price increase
- Chloramphenicol (Devatis) eye oint 1%, 5 g – price increase and addition of PSS
- Chlortalidone [chlorthalidone] (Hygroton) tab 25 mg – addition of PSS

Summary of decisions – effective 1 September 2025 (continued)

- Clobetasol propionate (Dermol) crm and oint 0.05%, 30 g and scalp app 0.05%, 30 ml – price increase and addition of PSS
- Clonidine hydrochloride (Clonidine Teva) tab 25 mcg – price increase and addition of PSS
- Diatrizoate meglumine with sodium amidotrizoate (Gastrografin) oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle – new Pharmacode listing
- Digoxin tab 62.5 mcg (Lanoxin PG) and tab 250 mcg (Lanoxin) – price increase and addition of PSS
- Dihydrocodeine tartrate (DHC Continus) tab long-acting 60 mg – price increase and addition of PSS
- Dipyridamole (Dipyridamole – Strides) cap modified-release 200 mg – new listing
- Dipyridamole tab 25 mg, inj 5 mg per ml 2 ml ampoule, tab long-acting 150 mg (Pytazen SR) and cap modified-release 200 mg (Dipyridamole – Strides) – addition of restriction
- Droperidol (Droperidol Medsurge) inj 2.5 mg per ml, 1 ml ampoule – new listing and addition of PSS
- Droperidol (Droperidol Panpharma) inj 2.5 mg per ml, 1 ml ampoule – to be delisted 1 February 2026
- Emulsifying ointment (Evara Emulsifying Ointment) oint BP, 500 g – amended brand name
- Ferrous sulfate (Ferrograd) tab long-acting 325 mg (105 mg elemental) – addition of restriction and to be delisted 1 March 2026
- Ferrous sulfate (Ferro-Liquid) oral liq 30 mg (6 mg elemental) per 1 ml, 250 ml – new listing and addition of PSS
- Ferrous sulfate (Ferdan) oral liq 30 mg (6 mg elemental) per 1 ml, 500 ml – to be delisted 1 February 2026
- Fexofenadine hydrochloride (Fexaclear) tab 120 mg – new Pharmacode listing
- Fexofenadine hydrochloride (Fexaclear) tab 120 mg – Pharmacode 2698781 delisted 1 September 2025
- Gentamicin sulphate (Cidomycin P/Free, Gentamicin Amdipharm and Gentamicin Noridem) inj 40 mg per ml, 2 ml ampoule – to be delisted 1 December 2025
- Glycerol (Lax-suppositories Glycerol) suppos 2.8/4.0 g – price increase and addition of PSS
- Heparin sodium inj 1,000 iu per ml, 5 ml ampoule (Wockhardt and Wockhardt PSF) and inj 1,000 iu per ml, 10 ml vial (Pfizer) – to be delisted 1 January 2026
- Hydrocortisone (Noumed) crm 1%, 500 g – addition of PSS
- Labetalol (Presolol) tab 200 mg – new listing

Summary of decisions – effective 1 September 2025 (continued)

- Lactulose (Laevolac) oral liq 10 g per 15 ml, 500 ml – price increase and addition of PSS
- Lenalidomide (viatris) (Lenalidomide Viatris) cap 5 mg – new Pharmacode listing
- Lidocaine [lignocaine] hydrochloride gel 2%, 11 ml urethral syringe (Instillagel Lido) and spray 10%, 50 ml (Xylocaine) – price increase and addition of PSS
- Liothyronine sodium inj 10 mcg vial – new listing
- Loperamide hydrochloride (Diamide Relief) cap 2 mg – price increase and addition of PSS
- Methadone hydrochloride (AFT) inj 10 mg per ml, 1 ml vial – price increase
- Meningococcal B multicomponent vaccine (Bexsero) inj 175 mcg per 0.5 ml prefilled syringe – amended restriction criteria
- Morphine sulphate (Medsurge) inj 5 mg, 10 mg, 15 mg and 30 mg per ml, 1 ml ampoule – price increase and addition of PSS
- Neostigmine metilsulfate with glycopyrronium bromide (Max Health) inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – addition of PSS
- Nicorandil (Max Health) tab 10 mg and 20 mg – price increase and addition of PSS
- Nimodipine (Nimotop) tab 30 mg and inj 0.2 mg per ml, 50 ml vial – addition of PSS
- Noradrenaline (Noradrenaline Medsurge) inj 1 mg per ml, 4 ml ampoule – new listing and addition of PSS
- Noradrenaline (Noradrenaline BNM) inj 1 mg per ml, 4 ml ampoule – to be delisted 1 April 2026
- Ondansetron (Ondansetron-AFT) inj 2 mg per ml, 2 ml and 4 ml ampoule – price increase and addition of PSS
- Oral feed (Sustagen Hospital Formula (Chocolate and Vanilla)) powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can, 840 g – price increase
- Oxycodone hydrochloride (Oxycodone Amneal) tab immediate-release 5 mg, 10 mg and 20 mg – Pharmacodes 2681919, 2681927 and 2681935 delisted 1 September 2025, respectively
- Oxytocin with ergometrine maleate (Syntometrine) inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – price increase and addition of PSS
- Paracetamol (Paracetamol Kabi) inj 10 mg per ml, 100 ml vial – price increase and addition of PSS
- Paracetamol with codeine (Paracetamol + Codeine (Relieve)) tab paracetamol 500 mg with codeine phosphate 8 mg – price increase and addition of PSS
- Paroxetine (Loxamine) tab 20 mg – price increase and addition of PSS
- Paroxetine (Paxtine) tab 20 mg – new listing
- Pegfilgrastim (Ziextenzo) inj 6 mg per 0.6 ml syringe – price increase and addition of PSS

Summary of decisions – effective 1 September 2025 (continued)

- Pethidine hydrochloride (Noumed Pethidine) tab 50 mg – addition of PSS
- Phenoxymethylpenicillin [penicillin v] (AFT) grans for oral liq 125 mg per 5 ml and grans for oral liq 250 mg per 5 ml, 100 ml – price increase and addition of PSS
- Potassium chloride (Span-K) tab long-acting 600 mg (8 mmol) – price increase and addition of PSS
- Propofol (Fresofol 1% MCT/LCT) inj 10 mg per ml, 20 ml ampoule, 50 ml vial and 100 ml vial – price increase and addition of PSS
- Remdesivir (Veklury) inj 100 mg vial – price decrease, amended note and removal of restriction criteria
- Risedronate sodium (Risedronate Sandoz) tab 35 mg – price increase and addition of PSS
- Rivastigmine patch 4.6 mg per 24 hour (Rivastigmine Patch BNM 5) and patch 9.5 mg per 24 hour (Rivastigmine Patch BNM 10) – amended restriction criteria
- Salbutamol (UK Cipla) nebuliser soln 2 mg per ml, 2.5 ml ampoule – new listing
- Sodium citrate with sodium lauryl sulphoacetate (Micolette) enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – price increase and addition of PSS
- Sodium chloride (Fresenius Kabi) inj 0.9%, 5 ml, 10 ml and 20 ml ampoule – price increase and addition of PSS
- Sotalol (Mylan) tab 80 mg and 160 mg – price increase and addition of PSS
- Tamsulosin hydrochloride (Tamsulosin-Rex) cap 400 mcg – price increase and addition of PSS
- Tenoxicam (Tilcotil) tab 20 mg – price increase and addition of PSS
- Tetrabenazine (Motetis) tab 25 mg – price increase and addition of PSS
- Vinorelbine (Vinorelbine Te Arai) cap 20 mg, 30 mg and 80 mg – price increase and addition of PSS
- Zoledronic acid (Zoledronic Acid Viatriis) inj 5 mg per 100 ml, bag – price decrease and addition of PSS

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Section H changes to Part II

Effective 1 September 2025

ALIMENTARY TRACT AND METABOLISM

5	LOPERAMIDE HYDROCHLORIDE (↑ price and addition of PSS) Cap 2 mg – 5% DV Feb 26 to 2028	12.00	400	Diamide Relief
16	GLYCEROL (↑ price and addition of PSS) Suppos 2.8/4.0 g – 5% DV Feb 26 to 2028	12.39	20	Lax- suppositories Glycerol
	Note: DV limit applies to glycerol suppository presentations			
16	LACTULOSE (↑ price and addition of PSS) Oral liq 10 g per 15 ml – 5% DV Feb 26 to 2028	6.16	500 ml	Laevolac
16	SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE (↑ price and addition of PSS) Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml, 5 ml – 5% DV Feb 26 to 2028	36.89	50	Micolette
24	FERROUS SULFATE (delisting and addition of restriction) → Tab long-acting 325 mg (105 mg elemental) – Restricted: For continuation only	2.55	30	Ferrograd
	Note – Ferrograd tab long-acting 325 mg (105 mg elemental) to be delisted 1 March 2026.			
34	FERROUS SULFATE (new listing and addition of PSS) Oral liq 30 mg (6 mg elemental) per 1 ml – 5% DV Feb 26 to 2028	10.25	250 ml	Ferro-Liquid
34	FERROUS SULFATE (delisting) Oral liq 30 mg (6 mg elemental) per 1 ml	13.10	500 ml	Ferodan
	Note – Ferodan oral liq 30 mg (6 mg elemental) per 1 ml, 500 ml to be delisted 1 February 2026.			

BLOOD AND BLOOD FORMING ORGANS

37	HEPARIN SODIUM (delisting) Inj 1,000 iu per ml, 5 ml ampoule	25.49	10	Wockhardt
		103.70		Wockhardt PSF
	Inj 1,000 iu per ml, 10 ml vial	127.44	25	Pfizer
	Note – Wockhardt and Wockhardt PSF inj 1,000 iu per ml, 5 ml ampoule and Pfizer inj 1,000 iu per ml, 10 ml vial to be delisted 1 January 2026.			
37	DIPYRIDAMOLE (new listing) → Cap modified-release 200 mg	55.13	60	Dipyridamole – Strides
37	DIPYRIDAMOLE – Restricted: For continuation only (addition of restriction) → Tab 25 mg → Inj 5 mg per ml, 2 ml ampoule → Tab long-acting 150 mg	13.93	60	Pytazen SR
	→ Cap modified-release 200 mg	55.13	60	Dipyridamole – Strides
37	ASPIRIN (delisted) Tab 100 mg – 5% DV Jun-24 to 2026	1.95	90	Ethics Aspirin EC
	Note – Ethics Aspirin EC tab 100 mg, 90 tab pack delisted 1 September 2025.			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2025 (continued)

40	PEGFILGRASTIM († price and addition of PSS) → Inj 6 mg per 0.6 ml syringe – 5% DV Feb 26 to 2028	69.50	1	Ziextenzo
42	SODIUM CHLORIDE († price and addition of PSS) Inj 0.9%, 5 ml ampoule – 5% DV Feb 26 to 2028	4.12	20	Fresenius Kabi
	Inj 0.9%, 10 ml ampoule – 5% DV Feb 26 to 2028	7.50	50	Fresenius Kabi
	Inj 0.9%, 20 ml ampoule – 5% DV Feb 26 to 2028	5.20	20	Fresenius Kabi
43	POTASSIUM CHLORIDE († price and addition of PSS) Tab long-acting 600 mg (8 mmol) – 5% DV Feb 26 to 2028 ...	16.15	200	Span-K

CARDIOVASCULAR SYSTEM

46	AMIODARONE HYDROCHLORIDE († price and addition of PSS) Tab 100 mg – 5% DV Feb 26 to 2028	4.95	30	Aratac
	Tab 200 mg – 5% DV Feb 26 to 2028	5.86	30	Aratac
	Inj 50 mg per ml, 3 ml ampoule – 5% DV Feb 26 to 2028	17.96	10	Max Health
46	DIGOXIN († price and addition of PSS) Tab 62.5 mcg – 5% DV Feb 26 to 2028	8.58	240	Lanoxin PG
	Tab 250 mcg – 5% DV Feb 26 to 2028	18.75	240	Lanoxin
47	LABETALOL (new listing) Tab 200 mg.....	42.07	100	Presolol
48	SOTALOL († price and addition of PSS) Tab 80 mg – 5% DV Feb 26 to 2028	40.00	500	Mylan
	Tab 160 mg – 5% DV Feb 26 to 2028	20.00	100	Mylan
49	NIMODIPINE (addition of PSS) Tab 30 mg – 5% DV Feb 26 to 2028	350.00	100	Nimotop
	Inj 0.2 mg per ml, 50 ml vial – 5% DV Feb 26 to 2028	337.50	5	Nimotop
49	CLONIDINE HYDROCHLORIDE († price and addition of PSS) Tab 25 mcg – 5% DV Feb 26 to 2028	29.74	112	Clonidine Teva
51	CHLORTALIDONE [CHLORTHALIDONE] (addition of PSS) Tab 25 mg – 5% DV Feb 26 to 2028	6.95	50	Hygroton
54	NORADRENALINE (brand change and addition of PSS) Inj 1 mg per ml, 4 ml ampoule – 5% DV Apr 26 to 2028	32.78	10	Noradrenaline Medsurge
	Note – Noradrenaline BNM inj 1 mg per ml, 4 ml ampoule to be delisted 1 April 2026.			
55	NICORANDIL († price and addition of PSS) Tab 10 mg – 5% DV Feb 26 to 2028	27.81	60	Max Health
	Tab 20 mg – 5% DV Feb 26 to 2028	35.12	60	Max Health

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2025 (continued)

DERMATOLOGICALS

70	EMULSIFYING OINTMENT (amended brand name) Oint BP, 500 g – 5% DV May-24 to 2026 3.13	500 g	Evara Emulsifying Ointment ABE
	Note: DV limit applies to pack sizes of greater than 200 g.		
71	CLOBETASOL PROPIONATE (↑ price and addition of PSS) Crm 0.05% – 5% DV Feb 26 to 2028 3.75	30 g	Dermol
	Oint 0.05% – 5% DV Feb 26 to 2028 3.68	30 g	Dermol
71	HYDROCORTISONE (addition of PSS) Crm 1%, 500 g – 5% DV Feb 26 to 2028 20.40	500 g	Noumed
	Note: DV limit applies to the pack sizes of greater than 100 g.		
73	CLOBETASOL PROPIONATE (↑ price and addition of PSS) Scalp app 0.05% – 5% DV Feb 26 to 2028 6.90	30 ml	Dermol

GENITO-URINARY SYSTEM

75	OXYTOCIN WITH ERGOMETRINE MALEATE (↑ price and addition of PSS) Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml ampoule – 5% DV Feb 26 to 2028 41.47	5	Syntometrine
76	TAMSULOSIN HYDROCHLORIDE (↑ price and addition of PSS) → Cap 400 mcg – 5% DV Feb 26 to 2028 28.56	100	Tamsulosin-Rex

HORMONE PREPARATIONS

87	LIOTHYRONINE SODIUM (new listing) Inj 10 mcg vial
----	--

INFECTIONS

89	GENTAMICIN SULPHATE (delisting) Inj 40 mg per ml, 2 ml ampoule	36.70	5	Cidomycin P/Free
		18.38	10	Gentamicin Amdipharm
		91.90	50	Gentamicin Noridem
	Note – Cidomycin P/Free, Gentamicin Amdipharm and Gentamicin Noridem to be delisted 1 December 2025.			
90	CEFACLOR (↑ price and addition of PSS) Cap 250 mg – 5% DV Feb 26 to 2028	29.73	100	Ranbaxy-Cefaclor
	Grans for oral liq 25 mg per ml – 5% DV Feb 26 to 2028	5.83	100 ml	Ranbaxy-Cefaclor
91	CEFTRIAXONE (↑ price and addition of PSS) Inj 500 mg vial – 5% DV Feb 26 to 2028	0.94	1	Ceftriaxone-AFT
	Inj 2 g vial – 5% DV Feb 26 to 2028	8.15	5	Ceftriaxone-AFT
91	CEFTRIAXONE (↓ price and addition of PSS) Inj 1 g vial – 5% DV Feb 26 to 2028	3.49	5	Ceftriaxone-AFT

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2025 (continued)

93	AMOXICILLIN (↑ price and addition of PSS) Cap 250 mg – 5% DV Feb 26 to 2028	54.00	500	Miro-Amoxicillin
93	BENZATHINE BENZYLPENICILLIN (new listing) Inj 900 mg (1.2 million units) vial	43.24	1	Benzetacil
94	PHENOXYMETHYLPENICILLIN [PENICILLIN V] (↑ price and addition of PSS) Grans for oral liq 125 mg per 5 ml – 5% DV Feb 26 to 2028	5.75	100 ml	AFT
	Grans for oral liq 250 mg per 5 ml – 5% DV Feb 26 to 2028	5.89	100 ml	AFT
105	ABACAIR SULPHATE WITH LAMIVUDINE (↑ price and addition of PSS) → Tab 600 mg with lamivudine 300 mg – 5% DV Feb 26 to 2028	35.00	30	Abacavir/ lamivudine Viatris
108	ACICLOVIR (↑ price and addition of PSS) Tab dispersible 200 mg – 5% DV Feb 26 to 2028	2.05	25	Lovir
	Tab dispersible 400 mg – 5% DV Feb 26 to 2028	7.55	56	Lovir
	Tab dispersible 800 mg – 5% DV Feb 26 to 2028	7.43	35	Lovir
111	REMSDESIVIR (↓ price and amended note and removal of restriction criteria) <i>Note: Remdesivir to be provided to Health NZ Hospitals at a cost of \$0.00 as stock has been purchased directly by Pharmac.</i> <i>Note: For patients meeting access criteria for oral antiviral treatments (as on Pharmac's website).</i> → Inj 100 mg vial	615.23	1	Veklury
	Restricted Initiation – Treatment of mild to moderate COVID-19 Only if patient meets access criteria (as per https://pharmac.govt.nz/covid-oral-antivirals). Note the supply of treatment is via Pharmac's approved distribution process. Refer to the Pharmac website for more information about this and stock availability. Initiation – COVID-19 in hospitalised patients <i>Therapy limited to 5 doses</i> All of the following: 1 Patient is hospitalised with confirmed (or probable) symptomatic COVID-19; and 2 Patient is considered to be at high risk of progression to severe disease; and 3 Patient's symptoms started within the last 7 days; and 4 Patient does not require, or is not expected to require, mechanical ventilation; and 5 Not to be used in conjunction with other funded COVID-19 antiviral treatments; and 6 Treatment not to exceed five days.			
114	ATAZANAVIR SULPHATE (↑ price and addition of PSS) → Cap 150 mg – 5% DV Feb 26 to 2028	102.50	60	Atazanavir Viatris
	→ Cap 200 mg – 5% DV Feb 26 to 2028	152.30	60	Atazanavir Viatris

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2025 (continued)

MUSCULOSKELETAL SYSTEM

114	NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE (addition of PSS) Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – 5% DV Feb 26 to 2028	26.13	10	Max Health
114	RISEDRONATE SODIUM (↑ price and addition of PSS) Tab 35 mg – 5% DV Feb 26 to 2028	3.00	4	Risedronate Sandoz
114	ZOLEDRONIC ACID (↓ price and addition of PSS) Inj 5 mg per 100 ml, bag – 5% DV Feb 26 to 2028	19.45	1	Zoledronic Acid Viatrix
118	CELECOXIB (brand change and addition of PSS) Cap 100 mg – 5% DV Feb 26 to 2028	3.60	60	Celebrex
	Note – Celecoxib Pfizer cap 100 mg to be delisted to be 1 February 2026.			
119	TENOICAM (↑ price and addition of PSS) Tab 20 mg – 5% DV Feb 26 to 2028	23.50	100	Tilcotil

NERVOUS SYSTEM

120	TETRABENAZINE (↑ price and addition of PSS) Tab 25 mg – 5% DV Feb 26 to 2028	126.02	112	Motetis
120	BENZATROPINE MESYLATE (↑ price) Tab 2 mg.....	10.99	60	Benztrop
122	PROPOFOL (↑ price and addition of PSS) Inj 10 mg per ml, 20 ml ampoule – 5% DV Feb 26 to 2028	5.75	5	Fresofol 1% MCT/LCT
	Inj 10 mg per ml, 50 ml vial – 5% DV Feb 26 to 2028	27.50	10	Fresofol 1% MCT/LCT
	Inj 10 mg per ml, 100 ml vial – 5% DV Feb 26 to 2028	39.90	10	Fresofol 1% MCT/LCT
123	BUPIVACAINE HYDROCHLORIDE WITH FENTANYL (↑ price and addition of PSS) Inj 1.25 mg with fentanyl 2 mcg per ml, 100 ml bag – 5% DV Feb-26 to 2028	135.00	5	Bupafen
	Inj 1.25 mg with fentanyl 2 mcg per ml, 200 ml bag – 5% DV Feb-26 to 2028	138.00	5	Bupafen
123	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (↑ price and addition of PSS) Gel 2%, 11 ml urethral syringe – 5% DV Feb-26 to 2028	65.45	10	Instillagel Lido
	Spray 10% – 5% DV Feb-26 to 2028	82.90	50 ml	Xylocaine
124	PARACETAMOL (↑ price and addition of PSS) → Inj 10 mg per ml, 100 ml vial – 5% DV Feb-26 to 2028	15.30	10	Paracetamol Kabi
125	DIHYDROCODEINE TARTRATE (↑ price and addition of PSS) Tab long-acting 60 mg – 5% DV Feb-26 to 2028	9.20	60	DHC Continus

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2025 (continued)

125	MORPHINE SULPHATE (↑ price and addition of PSS)			
	Inj 5 mg per ml, 1 ml ampoule – 5% DV Feb-26 to 2028	5.96	5	Medsurge
	Inj 10 mg per ml, 1 ml ampoule – 5% DV Feb-26 to 2028	4.99	5	Medsurge
	Inj 15 mg per ml, 1 ml ampoule – 5% DV Feb-26 to 2028	6.93	5	Medsurge
	Inj 30 mg per ml, 1 ml ampoule – 5% DV Feb-26 to 2028	7.28	5	Medsurge
126	METHADONE HYDROCHLORIDE (↑ price)			
	Inj 10 mg per ml, 1 ml vial	72.99	10	AFT
126	OXYCODONE HYDROCHLORIDE (delisted)			
	Tab immediate-release 5 mg.....	13.77	100	Oxycodone Amneal
	Tab immediate-release 10 mg.....	18.77	100	Oxycodone Amneal
	Tab immediate-release 20 mg.....	26.77	100	Oxycodone Amneal
	Note – Pharmacodes 2681919, 2681927 and 2681935 delisted 1 September 2025, respectively.			
127	PARACETAMOL WITH CODEINE (↑ price and addition of PSS)			
	Tab paracetamol 500 mg with codeine phosphate 8 mg – 5% DV Feb-26 to 2028	31.95	1,000	Paracetamol + Codeine (Relieve)
127	PETHIDINE HYDROCHLORIDE (addition of PSS)			
	Tab 50 mg – 5% DV Feb-26 to 2028	8.68	10	Noumed Pethidine
128	PAROXETINE (↑ price and addition of PSS)			
	Tab 20 mg – 5% DV Feb-26 to 2028	4.98	90	Loxamine
128	PAROXETINE (new listing)			
	Tab 20 mg.....	1.66	30	Paxtine
129	CARBAMAZEPINE (delisted)			
	Tab 200 mg.....	14.53	100	Tegretol AU
	Note – Tegretol AU tab 200 mg delisted 1 September 2025.			
133	DROPERIDOL (brand change and addition of PSS)			
	Inj 2.5 mg per ml, 1 ml ampoule – 5% DV Feb-26 to 2028	28.68	10	Droperidol Medsurge
	Note – Droperidol Panpharma inj 2.5 mg per ml, 1 ml ampoule to be delisted 1 February 2026.			
133	ONDANSETRON (↑ price and addition of PSS)			
	Inj 2 mg per ml, 2 ml ampoule – 5% DV Feb-26 to 2028	1.54	5	Ondansetron-AFT
	Inj 2 mg per ml, 4 ml ampoule – 5% DV Feb-26 to 2028	2.14	5	Ondansetron-AFT
146	RIVASTIGMINE (amended restriction criteria – affected criteria shown only)			
	➔ Patch 4.6 mg per 24 hour – 5% DV Mar-25 to 2027	49.40	30	Rivastigmine Patch BNM 5
	➔ Patch 9.5 mg per 24 hour – 5% DV Mar-25 to 2027	49.40	30	Rivastigmine Patch BNM 10
	Restricted			
	Initiation			
	Re-assessment required after 6 months			
	Both:			
	1 The patient has been diagnosed with dementia; and			
	2 The patient is contraindicated to or has experienced intolerable nausea and/or vomiting side effects from donepezil tablets.			

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2025 (continued)

ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

151	CAPECITABINE (↑ price and addition of PSS)			
	Tab 150 mg – 5% DV Feb-26 to 2028	10.92	60	Capecitabine Viatris
	Tab 500 mg – 5% DV Feb-26 to 2028	50.96	120	Capecitabine Viatris
153	LENALIDOMIDE (VIATRIS) (new Pharmacode listing)			
	→ Cap 5 mg – 5% DV Feb-25 to 31 Jan 2028	76.92	21	Lenalidomide Viatris
	Note – this is a new Pharmacode listing 2707527.			
258	AZATHIOPRINE (↑ price and addition of PSS)			
	Tab 25 mg – 5% DV Feb-26 to 2028	10.15	60	Azamun
	Tab 50 mg – 5% DV Feb-26 to 2028	10.34	100	Azamun
172	VINORELBINE (↑ price and addition of PSS)			
	Cap 20 mg – 5% DV Feb-26 to 2028	32.10	1	Vinorelbine Te Arai
	Cap 30 mg – 5% DV Feb-26 to 2028	42.80	1	Vinorelbine Te Arai
	Cap 80 mg – 5% DV Feb-26 to 2028	80.00	1	Vinorelbine Te Arai
183	ADALIMUMAB (AMGEVITA) (amended restriction criteria – affected criteria shown only)			
	→ Inj 20 mg per 0.4 ml prefilled syringe			
	– 5% DV Oct-22 to 31 Jul 2026	190.00	1	Amgevita
	→ Inj 40 mg per 0.8 ml prefilled pen			
	– 5% DV Oct-22 to 31 Jul 2026	375.00	2	Amgevita
	→ Inj 40 mg per 0.8 ml prefilled syringe			
	– 5% DV Oct-22 to 31 Jul 2026	375.00	2	Amgevita
	Restricted			
	Initiation – Arthritis - rheumatoid			
	Rheumatologist			
	<i>Re-assessment required after 6 months</i>			
	Either:			
	1 Both:			
	1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and			
	1.2 Either:			
	1.2.1 The patient has experienced intolerable side effects; or			
	1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for rheumatoid arthritis; or			
	2 All of the following:			
	2.1 Patient has had rheumatoid arthritis (either confirmed by radiology imaging, or the patient is cyclic citrullinated peptide (CCP) antibody positive) for six months duration or longer; and			
	2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and			
	2.3 Patient has tried and not responded to at least three months of methotrexate at a maximum tolerated dose (unless contraindicated); and			
	2.4 Patient has tried and not responded to at least three months of methotrexate in combination with sulfasalazine and hydroxychloroquine sulphate at maximum tolerated doses (unless contraindicated); and			
	2.5 Either:			
	2.5.1 Patient has tried and not responded to at least three months of methotrexate in combination with the maximum tolerated dose of ciclosporin (unless contraindicated); or			
	2.5.2 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide (unless contraindicated) alone or in combination with methotrexate; and			

continued...

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2025 (continued)

continued...

2.6 Either:

- 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen joints; or
 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip.

RESPIRATORY SYSTEM AND ALLERGIES

265	FEXOFENADINE HYDROCHLORIDE (new Pharmacode listing) Tab 120 mg – 5% DV Jul-25 to 2027	3.49	30	Fexaclear
	Note – this is a new Pharmacode listing 2711222.			
265	FEXOFENADINE HYDROCHLORIDE (delisted) Tab 120 mg – 5% DV Jul-25 to 2027	3.49	30	Fexaclear
	Note – this delist applies to Pharmacode 2698781, delisted 1 September 2025.			
269	SALBUTAMOL (new listing) Nebuliser soln 2 mg per ml, 2.5 ml ampoule	9.43	20	UK Cipla

SENSORY ORGANS

274	CHLORAMPHENICOL (↑ price and addition of PSS) Eye oint 1% – 5% DV Feb-26 to 2028	1.55	5 g	Devatis
-----	--	------	-----	----------------

VARIOUS

282	CHARCOAL (↑ price) Oral liq 200 mg per ml	59.85	250 ml	Carbasorb-X
284	DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE (new Pharmacode listing) Oral liq 660 mg per ml with sodium amidotrizoate 100 mg per ml, 100 ml bottle	30.00	100 ml	Gastrografin
	Note – listing is for Pharmacode 2698730.			

SPECIAL FOODS

298	AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) (new listing) → Liquid (juicy berries), 20 g protein, 12.75 g carbohydrate and 0.46 g fat and 0 g fibre per 125 ml pouch	1,684.80	30	TYR Lophlex LQ 20
298	AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE) (delisting) → Liquid (juicy berries), 20 g protein, 8.8 g carbohydrate 0.44 g fat and 0.5 g fibre per 125 ml pouch	1,684.80	30	TYR Lophlex LQ 20
	Note – TYR Lophlex LQ 20 liquid (juicy berries), 20 g protein, 8.8 g carbohydrate 0.44 g fat and 0.5 g fibre per 125 ml pouch to be delisted from 1 December 2025.			
308	ORAL FEED (↑ price) → Powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can	15.90	840 g	Sustagen Hospital Formula (Chocolate) Sustagen Hospital Formula (Vanilla)

→ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	------------------------------------	-----	-------------------------------------

Changes to Section H Part II – effective 1 September 2025 (continued)

VACCINES

312 MENINGOCOCCAL B MULTICOMPONENT VACCINE (amended restriction criteria – affected criteria shown only)

→ Inj 175 mcg per 0.5 ml prefilled syringe	0.00	1	Bexsero
		10	Bexsero

Restricted

Initiation – Primary immunisation for children up to **12 59** months of age **inclusive**

Therapy limited to 3 doses

A primary course of up to three doses (dependent on age at first dose) for previously unvaccinated children up to the age of 59 months inclusive.

Either:

- 1 Three doses for children up to 12 months of age (inclusive) for primary immunisation; or
- 2 Up to three doses (dependent on age at first dose) for a catch-up programme for children from 13 months to 59 months of age (inclusive) for primary immunisation, from 1 March 2023 to 31 August 2025.

Initiation – Person is one year of age or over **High-risk individuals 5 years of age or over**

Both:

1 Person is aged at least 5 years; and

2 Any of the following:

- 2.1 Up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; **or**
- 2.2 Up to two doses for close contacts of meningococcal cases of any group **Up to two doses and a booster every five years for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited); or**
- 2.3 Up to two doses for person who has previously had meningococcal disease of any group **Up to two doses and a booster every five years pre- or post-solid organ transplant; or**
- 2.4 Up to two doses for bone marrow transplant patients **Up to two doses for close contacts of meningococcal cases of any group; or**
- 2.5 Up to two doses for person pre- and post-immunosuppression* **Up to two doses for person who has previously had meningococcal disease of any group; or**
- 2.6 **Up to two doses for bone marrow transplant patients; or**
- 2.7 **Up to two doses for person pre- and post-immunosuppression*.**

*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

Index

Pharmaceuticals and brands

A	
Abacavir/ lamivudine Viatris.....	10
ABACAVIR SULPHATE WITH LAMIVUDINE	10
ACICLOVIR	10
ADALIMUMAB (AMGEVITA)	13
Amgevita	13
AMINO ACID FORMULA (WITHOUT PHENYLALANINE AND TYROSINE)	14
AMIODARONE HYDROCHLORIDE	8
AMOXICILLIN	10
Aratac	8
ASPIRIN.....	7
ATAZANAVIR SULPHATE	10
Atazanavir Viatris.....	10
Azamun	13
AZATHIOPRINE	13
B	
BENZATHINE BENZYL PENICILLIN	10
BENZATROPINE MESYLATE	11
Benzetacil	10
Benztrop	11
Bexsero	15
Bupafen	11
BUPIVACAINE HYDROCHLORIDE WITH FENTANYL.....	11
C	
CAPECITABINE	13
Capecitabine Viatris.....	13
CARBAMAZEPINE	12
Carbasorb-X.....	14
CEFACLOL.....	9
CEFTRIAXONE.....	9
Ceftriaxone-AFT	9
Celebrex.....	11
CELECOXIB.....	11
CHARCOAL.....	14
CHLORAMPHENICOL	14
CHLORTHALIDONE [CHLORTHALIDONE].....	8
CHLORTHALIDONE	8
Cidomycin P/Free.....	9
CLOBETASOL PROPIONATE.....	9
CLONIDINE HYDROCHLORIDE.....	8
Clonidine Teva	8
D	
Dermol.....	9
DHC Continus	11
Diamide Relief.....	7
DIATRIZOATE MEGLUMINE WITH SODIUM AMIDOTRIZOATE.....	14
DIGOXIN	8
DIHYDROCODEINE TARTRATE	11
DIPYRIDAMOLE	7
Dipyridamole – Strides	7
DROPERIDOL.....	12
Droperidol Medsurge.....	12
E	
EMULSIFYING OINTMENT	9
Emulsifying Ointment ADE.....	9
Ethics Aspirin EC.....	7
Evava Emulsifying Ointment.....	9
F	
Ferodan	7
Ferrograd	7
Ferro-Liquid	7
FERROUS SULFATE	7
Fexaclear	14
FEXOFENADINE HYDROCHLORIDE	14
Fresofol 1% MCT/LCT	11
G	
Gastrografin.....	14
Gentamicin Amdipharm.....	9
Gentamicin Noridem.....	9
GENTAMICIN SULPHATE.....	9
GLYCEROL	7
H	
HEPARIN SODIUM	7
HYDROCORTISONE.....	9
Hygroton.....	8
I	
Instillagel Lido.....	11
L	
LABETALOL	8
LACTULOSE.....	7
Laevolac	7
Lanoxin.....	8
Lanoxin PG	8
Lax- suppositories Glycerol	7
Lenalidomide Viatris	13
LENALIDOMIDE (VIATRIS).....	13
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE.....	11
LIGNOCAINE	11
LIOTHYRONINE SODIUM	9
LOPERAMIDE HYDROCHLORIDE	7
Lovir	10
Loxamine	12
M	
MENINGOCOCCAL B MULTICOMPONENT VACCINE	15
METHADONE HYDROCHLORIDE	12
Micolette	7
Miro-Amoxicillin.....	10
MORPHINE SULPHATE	12

Index

Pharmaceuticals and brands

Motetis	11	Risedronate Sandoz	11
N		RISEDRONATE SODIUM.....	11
NEOSTIGMINE METILSULFATE WITH		RIVASTIGMINE.....	12
GLYCOPYRRONIUM BROMIDE	11	Rivastigmine Patch BNM 5	12
NICORANDIL	8	Rivastigmine Patch BNM 10.....	12
NIMODIPINE.....	8	S	
Nimotop.....	8	SALBUTAMOL	14
NORADRENALINE	8	SODIUM CHLORIDE	8
Noradrenaline Medsurge.....	8	SODIUM CITRATE WITH SODIUM LAURYL	
Noumed Pethidine	12	SULPHOACETATE	7
O		SOTALOL.....	8
ONDANSETRON	12	Span-K	8
Ondansetron-AFT.....	12	Sustagen Hospital Formula (Chocolate)	14
ORAL FEED	14	Sustagen Hospital Formula (Vanilla)	14
Oxycodone Amneal.....	12	Syntometrine.....	9
OXYCODONE HYDROCHLORIDE	12	T	
OXYTOCIN WITH ERGOMETRINE MALEATE.....	9	TAMSULOSIN HYDROCHLORIDE.....	9
P		Tamsulosin-Rex.....	9
PARACETAMOL	11	Tegretol AU.....	12
Paracetamol + Codeine (Relieve).....	12	TENOXICAM.....	11
Paracetamol Kabi.....	11	TETRABENAZINE.....	11
PARACETAMOL WITH CODEINE.....	12	Tilcotil.....	11
PAROXETINE.....	12	TYR Lophlex LQ 20	14
Paxtine.....	12	U	
PEGFILGRASTIM.....	8	UK Cipla.....	14
PENICILLIN V.....	10	V	
PETHIDINE HYDROCHLORIDE	12	Veklury	10
PHENOXYMETHYLPENICILLIN [PENICILLIN V]	10	VINORELBINE	13
POTASSIUM CHLORIDE	8	Vinorelbine Te Arai	13
Presolol	8	X	
PROPOFOL	11	Xylocaine	11
Pytazen SR	7	Z	
R		Ziextenzo.....	8
Ranbaxy-Cefaclor.....	9	ZOLEDRONIC ACID	11
REMEDSIVIR.....	10	Zoledronic Acid Viatris.....	11

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - www.pharmac.govt.nz

Email: enquiry@pharmac.govt.nz

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.

